Luna, Pamela N.
Hasegawa, Kohei
Ajami, Nadim J.
Espinola, Janice A.
Henke, David M.
Petrosino, Joseph F.
Piedra, Pedro A.
Sullivan, Ashley F.
Camargo, Carlos A. Jr.
Shaw, Chad A.
Mansbach, Jonathan M.
Funding for this research was provided by:
National Institutes of Health (U01 AI-087881, R01 AI-114552, R01 AI-108588, UG3 OD-023253)
Article History
Received: 27 December 2016
Accepted: 14 December 2017
First Online: 3 January 2018
Ethics approval and consent to participate
: Written informed consent was obtained from the parent or guardian of all participating infants. The institutional review board at each of the participating hospitals approved the study.
: Not applicable.
: JMM has provided bronchiolitis-related consultation for Regeneron. NJA and JFP own shares at Diversigen Inc., a microbiome research company. PAP provided bronchiolitis-related consultation for Gilead, Novavax, Ablynx, and Regeneron. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.